NOVN.SW
NOVN.SW
CH0012005267
NOVARTIS N
Loading chart...
Solid Quality Asset with Moderate Fluctuation

Healthy balance: Exemplary business financials (Health Score: 67/100) paired with moderate price swings for a single equity (±19.4% p.a.). The score (5/7) reflects the standard baseline for equities under SRI rules.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
5/7 Elevated
5 / 7 SRI Price Fluctuation & Beta

Above-average volatility. Suitable for experienced investors with high risk tolerance (5+ years horizon). Moves noticeably less than the broader market (0.5x).

Beta (Market Relation)
0.47x
Defensive
Volatility (5Y p.a.)
19.4% p.a.
5-Year Horizon
Max Drawdown (5Y)
-19.2%
5-Year Horizon
Sharpe Ratio
0.41
Return / Risk
Elevated Risk / Growth: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +11.7%
3 Years 20.4% -19.2% 0.38 +10.1%
5 Years 19.4% -19.2% 0.41 +10.4%
10 Years 19.0% -27.0% 0.21 +6.4%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
1 ISS Score: 1 / 10
Audit Risk
1 ISS Score: 1 / 10
Board Risk
2 ISS Score: 2 / 10
Short Ratio
-
ende